BioCentury | Aug 15, 2016
Clinical News

MCB3837 regulatory update

...is a water-soluble, IV prodrug of Morphochem’s MCB3681, a small molecule quinolonyl-oxazolidinone antibiotic. This half, Morphochem...
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...NASDAQ:AMGN) (A) Developed rapid antibody screening technology 2000 $10M series B 2000 International Biotechnology Trust Morphochem...
BioCentury | Aug 28, 2006
Company News

4-Antibody management update

...Germany Business: Antibodies Hired: Sijmen de Vries as CEO, formerly CEO of Biovertis AG 's Morphochem AG...
BioCentury | Aug 22, 2006
Company News

4-Antibody names CEO, raises $4.9M

...He replaces co-founder Ulf Grawunder, who will become CSO. Previously, de Vries was CEO of Morphochem...
BioCentury | Mar 20, 2006
Company News

Codexis management update

...general manager of Codexis' Codexis Enzymes and Intermediates unit, formerly VP of business development at Morphochem AG...
BioCentury | Feb 13, 2006
Strategy

Spin once; spin again

...into the clinic by 2008. But the company became clinical stage through its acquisition of Morphochem AG...
BioCentury | Dec 19, 2005
Tools & Techniques

Clipping Alzheimer's at the start

...U.K.), now a subsidiary of OSI Pharmaceuticals Inc. (OSIP, Melville, N.Y.). Probiodrug has partnered with Morphochem AG...
BioCentury | Dec 5, 2005
Strategy

Biovertis-Morphochem pipeline

...Biovertis-Morphochem pipeline Product Indication Status Oxaquin (A) Hospital-acquired infections Start Ph I in 06 Topoisomerase 1...
BioCentury | Dec 5, 2005
Strategy

Infectious ambition

...and Pharmexa A/S and BioVertis AG acquiring anti-infective assets from IDM Pharma Inc. and Morphochem AG...
...its own anti-infective ambitions, Biovertis (Vienna, Austria) swooped opportunistically to acquire the antibiotic assets of Morphochem...
...as well as all employees from both companies: 21 at Biovertis and 24 from Morphochem. Morphochem...
BioCentury | Dec 5, 2005
Company News

Biovertis, Morphochem deal

...Biovertis acquired Morphochem for stock, plus cash milestones. Further terms were not disclosed. Biovertis CEO Erich...
...Further terms were not disclosed. Biovertis CEO Erich Felber will be head of the newco. Morphochem...
...be a member of executive management. Biovertis said it will keep the R&D operations of Morphochem...
Items per page:
1 - 10 of 93
BioCentury | Aug 15, 2016
Clinical News

MCB3837 regulatory update

...is a water-soluble, IV prodrug of Morphochem’s MCB3681, a small molecule quinolonyl-oxazolidinone antibiotic. This half, Morphochem...
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...NASDAQ:AMGN) (A) Developed rapid antibody screening technology 2000 $10M series B 2000 International Biotechnology Trust Morphochem...
BioCentury | Aug 28, 2006
Company News

4-Antibody management update

...Germany Business: Antibodies Hired: Sijmen de Vries as CEO, formerly CEO of Biovertis AG 's Morphochem AG...
BioCentury | Aug 22, 2006
Company News

4-Antibody names CEO, raises $4.9M

...He replaces co-founder Ulf Grawunder, who will become CSO. Previously, de Vries was CEO of Morphochem...
BioCentury | Mar 20, 2006
Company News

Codexis management update

...general manager of Codexis' Codexis Enzymes and Intermediates unit, formerly VP of business development at Morphochem AG...
BioCentury | Feb 13, 2006
Strategy

Spin once; spin again

...into the clinic by 2008. But the company became clinical stage through its acquisition of Morphochem AG...
BioCentury | Dec 19, 2005
Tools & Techniques

Clipping Alzheimer's at the start

...U.K.), now a subsidiary of OSI Pharmaceuticals Inc. (OSIP, Melville, N.Y.). Probiodrug has partnered with Morphochem AG...
BioCentury | Dec 5, 2005
Strategy

Biovertis-Morphochem pipeline

...Biovertis-Morphochem pipeline Product Indication Status Oxaquin (A) Hospital-acquired infections Start Ph I in 06 Topoisomerase 1...
BioCentury | Dec 5, 2005
Strategy

Infectious ambition

...and Pharmexa A/S and BioVertis AG acquiring anti-infective assets from IDM Pharma Inc. and Morphochem AG...
...its own anti-infective ambitions, Biovertis (Vienna, Austria) swooped opportunistically to acquire the antibiotic assets of Morphochem...
...as well as all employees from both companies: 21 at Biovertis and 24 from Morphochem. Morphochem...
BioCentury | Dec 5, 2005
Company News

Biovertis, Morphochem deal

...Biovertis acquired Morphochem for stock, plus cash milestones. Further terms were not disclosed. Biovertis CEO Erich...
...Further terms were not disclosed. Biovertis CEO Erich Felber will be head of the newco. Morphochem...
...be a member of executive management. Biovertis said it will keep the R&D operations of Morphochem...
Items per page:
1 - 10 of 93